SCHEMBL2736610

SCHEMBL2736610

Cn1cccc(CSc2nc3ccccc3o2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.57
SMN1; SMN2 Q16637 10/20 0.57
RAB9A P51151 8/20 0.57
NPC1 O15118 7/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
MAPT P10636 7/20 0.56
LMNA P02545 5/20 0.56
TSHR P16473 8/20 0.51
PKM P14618 1/20 0.51
ALDH1A1 P00352 8/20 0.50
HPGD P15428 6/20 0.49
HSD17B10 Q99714 4/20 0.49
MAPK1 P28482 2/20 0.49
GAA P10253 1/20 0.49
HTT P42858 3/20 0.48
ALOX15 P16050 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GFER P55789 2/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL217275 0.84 ELANE (0.54) ELANESMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL16609345 0.75 ELANE (0.61) ELANESMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL2736611 0.75 CNR2 (0.43) ELANEMAPT
SCHEMBL2736620 0.73 ELANE (0.48) ELANESMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL4213126 0.73 MAPT (0.62) ELANESMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL31236783 0.72 SMN1; SMN2 (1.00) ELANESMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL16972936 0.70 HPGD (0.74) ELANESMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL774784 0.70 DDAH1 (0.65) ELANESMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL9752729 0.69 ALDH1A1 (0.57) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL27207542 0.69 RAB9A (0.50) ELANESMN1; SMN2RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027144-A1 Novel use of cannabinoid receptor agonist CNR2, CNR1, OPRM1 ELANE 1292/4885SMN1; SMN2 4206/4885RAB9A 997/4885
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R ELANE 4607/4885SMN1; SMN2 4652/4885RAB9A 2871/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 ELANE 512/4885SMN1; SMN2 3366/4885RAB9A 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.